Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

Size: px
Start display at page:

Download "Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats"

Transcription

1 THE JOURNAL OF INFECTIOUS DISEASES VOL. 124, SUPPLEMENT DECEMBER by the University of Chicago. All rights reserved. Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats J. Allan Wait, Eugene L. Moss, Jr., and Marvin J. Weinstein From the Microbiology Division, Schering Corporation, Bloomfield, New Jersey For determination of the importance of several factors affecting the vestibular toxicity of gentamicin in cats, several therapeutic regimens, routes of administration, and levels of dosage were examined. Cats were given high levels of gentamicin daily and observed for appearance of ataxia and impairment of the righting reflex. The time of appearance of ataxia was related to dosage. Death, attributed to renal toxicity, closely follows the appearance of ataxia after a dose of 60 mg/kg per day. At lower doses, there is a temporal separation between vestibular and renal toxicity. The renal damage is reversible, but the vestibular damage is not. Total dosage and duration of treatment appear to be more important factors than peak levels of drug in the serum with reference to time of appearance of ataxia at the dosage levels studied. The two major, potentially toxic effects associated with the aminoglycoside group of antibiotics are renal damage and damage to the vestibular or auditory functions of the eighth cranial nerve. Studies have shown that chronic administration of high doses ( mg/kg) of gentamicin produces nephrotoxicity in dogs [1] and vestibular dysfunction in cats [1-5]. In guinea pigs given high doses for several weeks, both labyrinthine and cochlear damage were noted [6-9]. This report examines the importance of some aspects of the vestibular toxicity of gentamicin in cats. Methods All preparations of gentamicin used were in the form of the sulfate dissolved in sterile distilled water and were given in terms of the base in a volume of 0.5 nil/kg. Cats were male mongrels obtained from a local supplier and weighed kg. All cats were conditioned for at least four weeks before use. Cats with indwelling cannulae in the carotid artery were prepared by Dr. W. Zeman, formerly of these laboratories, by procedures to be described elsewhere. During tests for ataxia, each cat was weighed daily and dropped from an inverted position 2 ft above a sponge-rubber mat for observation of impairment of righting reflex; cats were given gentamicin subcutaneously (except for those cats that received the drug intraarterially as discussed below). Animals were then observed for signs of ataxia as they traversed the room. Each cat was weighed, dropped, treated with drug, and walked daily, seven days each week (except as indicated). Each dose was given within 1 hr of 24 hr after the previous dose. Administration of gentamicin continued until frank ataxia or death occurred, except as noted below where treatment was reinstated after a rest period of one month. Assays of antibiotic were performed on I-ml samples of serum as described by Oden et al. [10]. Bacillus subtilis with a sensitivity of O.04g of gentamicin/ml was used. We thank Dr. William Zeman for preparing cannulated cats, Dr. Frank Fielder for histopathological evaluation, Mr. Edwin Oden for microbiological assays, and Mr. David Loebenberg for assistance with tests for ataxia. Please address requests for reprints to Dr. J. Allan Wait, Chemotherapy Department, Schering Corporation, Bloomfield, New Jersey Results One possible factor affecting the appearance of vestibular toxicity is level of the dosage. The results of a typical experiment with three levels of gentamicin sulfate are shown in table 1. The appearance of ataxia was obviously related to the S125

2 8126 Wait, Moss, and Weinstein Table 1. Chronic toxicity of gentamicin sulfate in cats given daily subcutaneous doses. Day righting Day Dose Day reflex of Cat (mg/kg/day) ataxic impaired death Mean > Mean > > > > Mean >62.8 NOTE. Days given are number of days elapsed after beginning of treatment with gentamicin. dose. Ataxia was observed after an average of 12.2 days at a level of 60 rug/kg per day, 17.2 days at a level of 40 mg/kg per day, and 31.4 days at a level of 20 rug/kg per day. Impairment of the righting reflex always occurred within one day of the appearance of ataxia. It has been suggested that ataxia occurs after renal damage is sufficient to result in increased levels of gentamicin in serum. The cats in this experiment were treated continuously until death or until day 70, when the experiment was terminated. At the highest dosage level, animals died 1-13 days (average, 5.2) after the appearance of ataxia. Death was attributable to the effects of renal tubular necrosis on the basis of histopathologic examination. Of the five cats receiving 40 rug/kg per day, four died within one to 10 days after becoming ataxic. As with the group that received the highest dose,.this group had necrosis of renal tubules. The remaining cat in this group survived more than 50 days of treatment with gentamicin after becoming ataxic. When this cat was sacrificed on day 70, mild renal tubular damage was observed. Of the group that received 20 mg/kg per day, one died 14 days after becoming ataxic, while three became ataxic on day 35 and survived another 35 days of treatment. Histopathologic examination of these cats killed on day 70 revealed mild or no renal tubular damage, thus showing a temporal separation of renal and vestibular toxicities. These results suggested an experiment to determine the reversibility of vestibular and renal aspects of toxicity. Three cats were given gentamicin subcutaneously at a dose of 40 mg/kg per day until ataxia appeared in 16, 18, and 19 days respectively. Treatment of all three cats was stopped at the time ataxia appeared. Based on the data in table 1, continued treatment might be expected to result in death within a few days. All animals were observed daily and remained ataxic until day 45 (29-32 days without treatment), when treatment was started again at the same level of gentamicin. The three cats died days after treatment recommenced. Histopathologic examination revealed the presence of renal tubular necrosis. The kidneys of these animals apparently were repaired sufficiently in the month of rest to permit another 20-day course of treatment before death. The ataxia was irreversible. The possibility that the appearance of ataxia might contain an idiosyncratic component was considered. Over the past two years, we have treated approximately 21 cats with gentamicin at a reference level of 40 rug/kg and fewer cats at other doses. Distribution curves for the day of appearance of ataxia are shown in figure 1. The frequency distribution as well as 100 r---"'---.--:.,--., r--r----., DAYS OF DOSING Figure 1. Percentage distribution curves of time of appearance of ataxia in cats given various amounts of gentamicin sulfate. Numbers of cats are given in parentheses

3 Chronic Toxicity of Gentamicin in Cats 8127 the cumulative distribution curves follow those of a normal distribution for the levels of 40 and 60 mg/kg per day. There was no evidence of clustering or a bimodal type of distribution which might be expected if some cats were significantly more or less sensitive to vestibular toxicity. The distribution for the 20 mg/kg per day level is flatter and suggests a range of responses. This may be due to the small number of animals studied and needs confirmation. The relationship between level of dose and time required to produce ataxia suggested an examination of total dose as a factor in vestibular toxicity. Figure 2 shows plots of total dose and number of days required for production of ataxia against the daily dose. Ataxia occurred after a smaller average total dose at lower dosage levels than at higher ones. This inverse relationship suggests that the length of treatment may be an important factor at the dosage levels studied. Two other experiments were performed for evaluation of the importance of total dose. In the first, two groups of five cats each were given 40 rug/kg per day. One group was given 40 mg/ kg five days a week, with rests on the weekend, and the other group was given 40 mg/kg per day seven days a week. Although the group treated five days each week took 25 days to become ataxic compared to 18 days for the group treated seven days a week, the total number of doses, 18, was the same for both groups, suggesting the importance of total dose and total number of days treated. loool: : J J 600 g S:2 30 x I- > In another study, one group of six cats was treated once a day with 40 mg/kg, while another group of five cats was given 20 mg/kg twice a day. The single daily treatment produced ataxia in an average of 17 days, while the group treated twice a day became ataxic in an average of 19.4 days. This slight difference was not significant as indicated by the range of 16 to 21 days in both groups. The average total dose for production of ataxia was higher with the split doses (776 mg/ kg) than with a single daily dose (680 mg/kg), Since gentamicin is rapidly excreted in the urine, it was thought that monitoring of levels of gentamicin in serum might provide a measure of renal function during the course of a study of ataxia. To provide an easy means of obtaining multiple samples of serum from cats, and also to permit evaluation of the relationship between peak serum levels and the appearance of ataxia, we prepared two cats with carotid artery cannulae. Initially, levels of gentamicin in serum were determined after a single subcutaneous dose of 40 mg/kg per day and were found to peak at approximately 100 ug/rnl one-half hour after treatment, with a rapid decline to less than 1 ug/ml 24 hr after treatment. The two cats were then started on a course of treatment of 40 mg/ kg per day, injected intraarterially. Levels of gentamicin in serum were monitored daily. Average serologic levels after intraarterial administration of gentamicin during the first two days of treatment are shown in figures 3 and 4. Peak levels after this route were two to six times Ẹ...! 100 ::J cr W Ul 10 <3 ;:! C) w DOSE (mg/kg) Figure 2. Relationship between dosage of gentamicin, time required to produce ataxia, and total dosage in cats. Eight cats received 60 mg/kg per day; 21, 40 mg/kg per day; and five, 20 mg/kg per day. 0.1 I I I o 2 :3 4 5 TIME (HOURS) Figure 3. Average levels of gentamicin in serum of cat 955 at various times after a single dose of 40 mg of gentamicin sulfate/ kg, given intraarterially (I.A.) or subcutaneously (S.C.).

4 S12 Walt, Moss, and Weinstein E <, 100 ::J cr W (fj w C> 0.1 "'----'--..._-.L.._--L...l-.._-l.-_---L..--rj"I---J o TIME (HOURS) Figure 4. Average levels of gentamicin in serum of cat 5314 at various times after a single dose of 40 mg of gentamicin sulfate/kg, given intraarterially (la.) or subcutaneously (S.C.). as high as after subcutaneous administration and declined rapidly to less than 1 ug/ml 24 hr after treatment. Levels in serum of these two cats given 40 mg/kg per day intraarterially daily for 20 days are shown in tables 2 and 3. Ataxia was noted in both cats on day 16. At the time ataxia appeared, a substantial decrease in renal function, as measured by the ability to excrete gentamicin, also occurred. This was most evident as an increase in levels in serum after 24 hr and progressed until the cats were sacrificed on day 20. Table 2. Levels of gentamicin in serum of cat 955 treated intraarterially with 40 mg of gentamicin/kg per day. Gentamicin in serum (ug/rnl) Day of at hr after injection treatment 1A Y: Ataxia Complete ataxia Table 3. Levels of gentamicin in serum of cat 5314 treated intraarterially with 40 mg of gentamicin/kg per day. Gentamicin in serum (ug/ml) at hr Day of after injection treatment 1A Y: Ataxia Complete ataxia Histopathologic examination revealed renal tubular necrosis. Discussion The data demonstrate that high levels of gentamicin sulfate administered daily to normal male cats produce ataxia and that the time of appearance of ataxia is related to dose. At a dose of 60 mg/kg per day (20-60 times the recommended daily dose for humans of 1-3 mg/kg per day), death, apparently as a result of renal tubular damage, follows the appearance of ataxia quite closely. At lower doses, a temporal separation of renal damage from vestibular damage becomes apparent. In a small number of cats, cessation of treatment after the appearance of ataxia permitted recovery from the renal damage. The vestibular damage, however, appeared to be irreversible. Administration by the intraarterial route demonstrated that at the high doses used, the magnitude of peak levels in serum was not solely responsible for the time of appearance of ataxia, since ataxia occurred after the same length of time whether the doses of 40 rug/kg were given subcutaneously or intraarterially, or whether it was given as 40 mg/kg once a day or 20 mg/kg twice a day. Total dose is important but is not the only factor involved. Cats given 60 rug/kg per day became ataxic in an average of 13.5 days; this

5 Chronic Toxicity of Gentamicin in Cats S129 represents an average total dose of 810 mg/kg, At 40 rag/kg per day, the total dose required to produce ataxia was 700 mg/kg, while at 20 mg/kg per day it was 628 rug/kg. This slight inverse relationship suggests that length of treatment is also an important factor in determining when ataxia will occur. References 1. Black, J., Calesnick, B., Williams, D., Weinstein, M. J. Pharmacology of gentamicin, a new broadspectrum antibiotic. Antimicrobial Agents and Chemotherapy-1963, p , Weinstein, M. J., Wagman, G. H., Taber, R. I. Toxicity of acetylated gentamicin and neomycin. Antimicrobial Agents and Chemotherapy-1965, p , Wagman, G. H., Oden, E. M., Weinstein, M. J., Irwin, S. Effect of calcium on the toxicity of gentamicin. Antimicrobial Agents and Chemotherapy-1966, p , Hawkins, J. E., Jr., Johnsson, L.-G., Aran, J.-M. Comparative tests of gentamicin ototoxicity. J. Infect. Dis. 119: , McGee, T. M., Webster, J., Williams, M. Histological and functional changes in the ears of cats after subcutaneous administration of gentamicin. J. Infect. Dis. 119: , Lundquist, P.-G., Wersall, J. The ototoxic effect of gentamicin-an electron microscopical study. In First international symposium on gentamicin, Paris, Jan., Schwabe, Basel, 1967, p Bernabei, L., Pierangeli, C. E., DiBrino, M., Consalvo, P. Contributo allo studio del danno labirintico sperimentale da gentamicina. 1. Rilievi funionali. Atti Accad. Fisiocr. Siena, Series 13, 16: , Bernabei, L., DiBrino, M., Consalvo, P., Pierangeli, C. E. Contributo allo studio del danno labirintico sperimentale da gentamicina. 2. Rilievi istopatologici. Atti Accad. Fisiocr. Siena, Series 13, 16: , Wright, I. Investigation of ototoxicity of an antibiotic from Micromonospora purpurea (gentamicin). J. Path. 98: , to. Oden, E. M., Stander, H., Weinstein, M. J. Microbiological assay of gentamicin. Antimicrobial Agents and Chemotherapy-1963, p. 8-13, 1964.

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS 390 CHEMOTHERAPY JULY 1967 GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS M. OHOKOSHI*, Y. NAIDE, T. KAWAMURA, K. SUZUKI,

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND

More information

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

Patients. Excludes paediatrics, neonates.

Patients. Excludes paediatrics, neonates. Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All

More information

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:

More information

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

MIACIN HIKMA PHARMACEUTICALS

MIACIN HIKMA PHARMACEUTICALS 09-15 MIACIN HIKMA PHARMACEUTICALS Amikacin (as sulfate) Solution for injection DESCRIPTION Amikacin sulfate is semi-synthetic aminoglycoside antibiotic derived from kanamycin. Clinical Pharmacology Intramuscular

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/803/01-FINAL November 2001 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GENTAMICIN SUMMARY REPORT

More information

Pharmacological Evaluation of Amikacin in Neonates

Pharmacological Evaluation of Amikacin in Neonates ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.

More information

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION Read all of this leaflet carefully before you start taking this

More information

DBL GENTAMICIN INJECTION BP

DBL GENTAMICIN INJECTION BP DBL GENTAMICIN INJECTION BP NAME OF THE MEDICINE Gentamicin Injection BP DESCRIPTION DBL Gentamicin Injection BP is a sterile solution containing in each ml: Gentamicin Sulphate BP equivalent to gentamicin

More information

EXCEDE Sterile Suspension

EXCEDE Sterile Suspension VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free

More information

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

1. NAME OF THE VETERINARY MEDICINAL PRODUCT Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and

More information

in Plastic Container Gentamicin Sulfate in 0.9% Sodium Chloride Injection

in Plastic Container Gentamicin Sulfate in 0.9% Sodium Chloride Injection Gentamicin Sulfate in 0.9% Sodium Chloride Injection in Plastic Container VIAFLEX Plus Container For Intravenous Administration Further Dilution Not Required Rx Only To reduce the development of drug-resistant

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/816/02-FINAL January 2002 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NEOMYCIN SUMMARY REPORT

More information

FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St.

FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St. FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St. Helier s Hospital Vancomycin and Gentamicin Audit Renal Unit St Helier Hospital

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

PRESCRIBING INFORMATION. Powder for Solution. Aminoglycoside Antibiotic

PRESCRIBING INFORMATION. Powder for Solution. Aminoglycoside Antibiotic PRESCRIBING INFORMATION Pr Streptomycin for Injection, U.S.P. Powder for Solution Aminoglycoside Antibiotic SteriMax Inc. 2770 Portland Drive, Oakville, ON L6H 6R4 Date of Revision: February 8, 2016 1

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

PRODUCT MONOGRAPH. GENTAMICIN (AS SULFATE) IN 0.9% SODIUM CHLORIDE INJECTION (1.0 mg/ml, 1.2 mg/ml, 1.6 mg/ml) ANTIBIOTIC

PRODUCT MONOGRAPH. GENTAMICIN (AS SULFATE) IN 0.9% SODIUM CHLORIDE INJECTION (1.0 mg/ml, 1.2 mg/ml, 1.6 mg/ml) ANTIBIOTIC PRODUCT MONOGRAPH Pr GENTAMICIN(E) GENTAMICIN (AS SULFATE) IN 0.9% SODIUM CHLORIDE INJECTION (1.0 mg/ml, 1.2 mg/ml, 1.6 mg/ml) ANTIBIOTIC BAXTER CORPORATION Mississauga, ON L5N 0C2 Date of Revision: November

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 8 1. NAME OF THE MEDICINAL PRODUCT Streptomycin (as sulfate) 1g powder for injection 1 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each glass vial contains

More information

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed. Mouse Formulary The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.): Intraperitoneal (IP) doses should not exceed 80 ml/kg

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES: CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

Product Information GENTAMICIN INJECTION BP NAME OF THE DRUG DESCRIPTION PHARMACOLOGY. Gentamicin Sulfate BP.

Product Information GENTAMICIN INJECTION BP NAME OF THE DRUG DESCRIPTION PHARMACOLOGY. Gentamicin Sulfate BP. Product Information GENTAMICIN INJECTION BP NAME OF THE DRUG Gentamicin Sulfate BP. DESCRIPTION Gentamicin sulfate is a mixture of the sulfates of antimicrobial substances produced by Micromonospora purpurea.

More information

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

PRODUCT MONOGRAPH. Gentamicin base (as sulfate) USP. 10 mg/ml and 40 mg/ml. Antibiotic

PRODUCT MONOGRAPH. Gentamicin base (as sulfate) USP. 10 mg/ml and 40 mg/ml. Antibiotic PRODUCT MONOGRAPH Pr GENTAMICIN INJECTION USP Gentamicin base (as sulfate) USP 10 mg/ml and 40 mg/ml Antibiotic Sandoz Canada Inc. 145, Jules-Léger Date of Revision: August 29, 2017 Boucherville, QC, Canada

More information

European public MRL assessment report (EPMAR)

European public MRL assessment report (EPMAR) 11 November 2013 EMA/CVMP/561830/2010 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) Neomycin (including framycetin) (All food producing species) On 29

More information

Speciality: Therapeutics

Speciality: Therapeutics Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which

More information

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

PRODUCT MONOGRAPH AMIKACIN SULFATE INJECTION USP. 250 mg/ml amikacin. Antibiotic

PRODUCT MONOGRAPH AMIKACIN SULFATE INJECTION USP. 250 mg/ml amikacin. Antibiotic PRODUCT MONOGRAPH Pr AMIKACIN SULFATE INJECTION USP 250 mg/ml amikacin Antibiotic Sandoz Canada Inc. Date of Revision: February 21, 2011 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Control no.: 100330

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Narketan-10 100 mg/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE

More information

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

Treatment of Gram-negative infections in patients before and after

Treatment of Gram-negative infections in patients before and after Postgrad. med. J. (April 1969) 45, 254-260. Treatment of Gram-negative infections in patients before and after renal transplantation Summary Sixty-six Gram-negative infections, occurring in thirty-four

More information

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere

More information

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

EPAR type II variation for Metacam

EPAR type II variation for Metacam 23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents

More information

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious

More information

Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle

Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin

More information

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations Back to Anesthesia/Pain Management Back to Table of Contents Front Page : Library : ACVC 2009 : Anesthesia/Pain Management : Dexmedetomidine Dexmedetomidine and its Injectable Anesthetic-Pain Management

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection

More information

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including: SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)

More information

by adding different antibiotics to sera containing

by adding different antibiotics to sera containing J. clin. Path., 1977, 30, 521-525 Serum gentamicin assays of 100 clinical serum samples by a rapid 40 C Kiebsiella method compared with overnight plate diffusion and acetyltransferase assays D. C. SHANSONI

More information

Plasma concentration monitoring of aminoglycosides. F. Follath, M. Wenk and S. Vozeh

Plasma concentration monitoring of aminoglycosides. F. Follath, M. Wenk and S. Vozeh Journal of A ntimicrobial Chemotherapy (1981)8, Suppl. A, 3 7-43 Plasma concentration monitoring of aminoglycosides F. Follath, M. Wenk and S. Vozeh Division of Clinical Pharmacology, Medical Department

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

DRUG GUIDELINE GENTAMICIN (SULFATE)

DRUG GUIDELINE GENTAMICIN (SULFATE) DRUG GUIDELINE GENTAMICIN (SULFATE) SCOPE (Area): FOR USE IN: All ward areas, except as outlined below EXCLUSIONS: Paediatrics (seek Paediatrician advice) SCOPE (Staff): Medical, Nursing and Pharmacy BRAND

More information

Streptomycin FOR INJECTION, USP

Streptomycin FOR INJECTION, USP Streptomycin FOR INJECTION, USP 10 DIGIT NDC STRENGTH SIZE WHOLESALE NUMBERS WEB LISTING 39822-0706-2 1 10 ABC 10033334 Cardinal 2833010 11 DIGIT NDC gram*/ vial vials McKesson 1898832 39822-0706-02 Morris

More information

Update on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015

Update on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Update on Therapeutic Drug Monitoring - Aminoglycosides Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust What are common

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline

More information

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET LABELLING AND PACKAGE LEAFLET A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE : Carton 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Alvegesic vet. 10 mg/ml Solution for injection for Horses, Dogs

More information

BIOTRANSFORMATION, A NEW APPROACH TO AMINOGLYCOSIDE BIOSYNTHESIS : II GENTAMICIN. R.T. TESTA and B.C. TILLEY

BIOTRANSFORMATION, A NEW APPROACH TO AMINOGLYCOSIDE BIOSYNTHESIS : II GENTAMICIN. R.T. TESTA and B.C. TILLEY 140 THE JOURNAL OF ANTIBIOTICS FEB. 1976 BIOTRANSFORMATION, A NEW APPROACH TO AMINOGLYCOSIDE BIOSYNTHESIS : II GENTAMICIN R.T. TESTA and B.C. TILLEY Schering Corporation, Bloomfield, New Jersey 07003,

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

PRESCRIBING AIDS FOR GENTAMICIN

PRESCRIBING AIDS FOR GENTAMICIN Br. J. clin. Pharmac. (197), 1, 5-5 PRSCRIBING AIDS FOR GNTAMICIN G.. MAWR, R. AHMAD, SYLVIA M. DOBBS & J.G. McGOUGH Departments of Pharmacology and Medicine, University of Manchester, Oxford Road, Manchester,

More information

Australian and New Zealand College of Veterinary Scientists. Membership Examination. Medicine of Cats Paper 1

Australian and New Zealand College of Veterinary Scientists. Membership Examination. Medicine of Cats Paper 1 Australian and New Zealand College of Veterinary Scientists Membership Examination June 2016 Medicine of Cats Paper 1 Perusal time: Fifteen (15) minutes Time allowed: Two (2) hours after perusal Answer

More information

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 500 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 500 mg cephalexin

More information

Antibiotic Usage Guidelines in Hospital

Antibiotic Usage Guidelines in Hospital SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The

More information

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption. A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection

More information

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 1000 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 1000 mg cephalexin

More information

New Insights into the Treatment of Leishmaniasis

New Insights into the Treatment of Leishmaniasis New Insights into the Treatment of Leishmaniasis Eric Zini Snow meeting, 14 March 2009 Few drugs available for dogs Initially developed to treat human leishmaniasis, later adopted in dogs None eradicates

More information

Rx, For use by or on the order of a licensed veterinarian.

Rx, For use by or on the order of a licensed veterinarian. A. General Information NADA Number: 140-915 Sponsor: Generic Name of Drug: Trade Name: Marketing Status: Novartis Animal Health Post Office Box 18300 Greensboro, NC 27419 Milbemycin Oxime INTERCEPTOR Flavor

More information

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com

More information

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL SYRINGE LABEL PRESCRIPTION ANIMAL REMEDY FOR ANIMAL TREATMENT ONLY VibraVet* 100 PASTE For Cats and Dogs 100 mg/g DOXYCYCLINE as monohydrate Infopest Verified Antibiotic READ LEAFLET BEFORE USE 2.5 g 2.0

More information

-1 - PRODUCT MONOGRAPH. GENTAMICIN SULFATE IN 0.9% SODIUM CHLORIDE INJECTION Gentamicin 0.8 mg/ml (as gentamicin sulfate)

-1 - PRODUCT MONOGRAPH. GENTAMICIN SULFATE IN 0.9% SODIUM CHLORIDE INJECTION Gentamicin 0.8 mg/ml (as gentamicin sulfate) -1 - PRODUCT MONOGRAPH GENTAMICIN SULFATE IN 0.9% SODIUM CHLORIDE INJECTION Gentamicin 0.8 mg/ml (as gentamicin sulfate) Gentamicin sulfate 80 mg/100 ml in Flexible (PVC) Containers Antibiotic Hospira

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

Procedure # IBT IACUC Approval: December 11, 2017

Procedure # IBT IACUC Approval: December 11, 2017 IACUC Procedure: Anesthetics and Analgesics Procedure # IBT-222.04 IACUC Approval: December 11, 2017 Purpose: The purpose is to define the anesthetics and analgesics that may be used in mice and rats.

More information

Cydectin. Fort Dodge PRODUCT DESCRIPTION

Cydectin. Fort Dodge PRODUCT DESCRIPTION Cydectin Fort Dodge moxidectin Injectable Solution for Beef and Nonlactating Dairy Cattle Antiparasitic Contains 10 mg moxidectin/ml Not for use in female dairy cattle of breeding age, veal calves, and

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance

More information

Comparative Clinical Pharmacology of Gentamicin, Sisomicin,

Comparative Clinical Pharmacology of Gentamicin, Sisomicin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1975, p. 396-401 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 4 Printed in U.S.A. Comparative Clinical Pharmacology of Gentamicin, Sisomicin,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN

More information

Original Research Article

Original Research Article Study of Preterm Infants with Different Gestational Age: Modifying Amikacin Sulphate Dosage Regimen 1 1,2 Bindiya Chauhan, Sunil S Jalalpure Dr. Prabhakar Kore Basic Science Research Center, KLE Academy

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers

More information

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

More information

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Therios 300 mg and 750 mg Palatable Tablets for Dogs Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

Comparison of the Nephrotoxicity of Netilmicin and

Comparison of the Nephrotoxicity of Netilmicin and ANTIMICRoBIAL AGENTs AND CHUMOTHKRAY, Oct. 1977, P. 474-478 Copyright 0 1977 American Society for Microbiology Vol. 12, No. 4 Printed in U.S.A. Comparison of the Nephrotoxicity of Netilmicin and Gentamicin

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

Acute Pyelonephritis POAC Guideline

Acute Pyelonephritis POAC Guideline Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml

More information

Diagnosis: Presenting signs and Symptoms include:

Diagnosis: Presenting signs and Symptoms include: PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective

More information

Metacam 1.5 mg/ml oral suspension for dogs

Metacam 1.5 mg/ml oral suspension for dogs Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active

More information